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Skeletal myogenesis is a highly complex and ordered 
process, entailing two main events [1,2]: (i) the specification 
of muscle precursors into myoblasts, followed by their 
differentiation into myocytes and (ii) the fusion of these 
differentiated myocytes giving rise to the multinucleated 
skeletal myofiber.
The class IIa Histone DeACetylases (HDACs)/MEF2 
(Myocyte Enhancer Factor-2) axis has long being 
considered as the master regulator of the differentiation 
process during skeletal myogenesis [3]. However, our 
recent work [4] demonstrates that this pathway is also 
crucial for fusion of myocytes into myofibers, both in 
vitro and in vivo. Our findings thus further confirm and 
expend the idea that the class IIa HDACs/MEF2 axis is a 
cornerstone of the myogenic process in vertebrates.
MEF2, the Historical Master Regulator of 
Myoblast Differentiation
Myoblast differentiation is coordinated by a hierarchical 
network of transcription factors, among which members 
of the MEF2 family, which includes MEF2a, -b, -c and -d 
play dominant roles [1,5]. MEF2 regulates the expression 
of a series of muscle structural genes and basic helix-
loop-helix  (bHLH) transcription factors involved in the 
differentiation program, that are collectively known as 
myogenic regulatory factors (MRFs) and include Myf5, 
MyoD, myogenin and MRF4 [1]. The transcriptional 
activity of MEF2 is controlled by class IIa HDACs 
(HDAC4, -5, -7, and -9) and by MITR, a HDAC9 paralog 
lacking a HDAC catalytic domain [6-8]. Interestingly, the 
ability of class IIa HDACs to bind to MEF2 is determined 
by the phosphorylation status of conserved serine residues 
located in their amino-terminal non-HDAC domain 
[9,10]. When not phosphorylated on these residues, class 
IIa HDACs bind to MEF2 and repress its transcriptional 
activity. In contrast, phosphorylation of class IIa HDACs 
induces their detachment from MEF2, which restores the 
activity of the transcription factor [11].
At the beginning of the 2000’s, it mainly was the founding 
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For several decades, the transcription factor MEF2 (myocyte enhancer factor-2) has been known as a master   regulator   of   myogenesis 
that   orchestrates   the   first   step   in   muscle   formation:  the differentiation of myoblasts into myocytes. Because of its importance 
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PP2A-Bδ  regulates  the  transcription  of  a  subset  of  MEF2-dependent  genes involved solely in myocyte fusion. Our observations 
demonstrate that, in contrast to the historical paradigm, MEF2 controls both early (i.e., the myoblast differentiation) and late (i.e., 
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work of the Olson laboratory that brought to light the 
central role of the class IIa HDACs/MEF2 pathway 
in skeletal muscle development and remodeling [12]. 
During skeletal muscle formation, the signal-responsive 
association with class IIa HDACs allows for a stage-
dependent control of MEF2 activity. Upon initiation of the 
differentiation program, the inhibitory activity of class IIa 
HDACs towards MEF2 is overcome by phosphorylation 
of their conserved serine residues by myogenic kinases 
[12,13]. This derepression allows MEF2 to cooperate with 
MyoD-related myogenic factors and promote skeletal 
muscle differentiation in vitro [11,14]. Historically, the role 
of the class IIa HDACs/MEF2 axis has thus been restricted 
to the early myoblastic differentiation events. Because the 
various approaches that were used to modulate the levels, 
activities or signal-responsiveness of class IIa HDACs had 
dramatic effects on myoblast differentiation [11-13,15], it 
has been very difficult so far to investigate any potential 
role of the class IIa/MEF2 pathway in later stages of 
skeletal muscle formation, such as myocyte fusion into 
myotubes.
The idea that the role of MEF2 during skeletal myogenesis 
was strictly limited to early differentiation is challenged 
by a careful survey of the literature. For instance, several 
studies have reported that MEF2 controls the transcription 
of genes involved in cytoskeleton structure and dynamics 
in muscle and non-muscle cells [16-20]. Cytoskeleton 
dynamics is required for proper cell-cell fusion, and 
accordingly many proteins important for myogenic fusion 
are components or regulators of the cytoskeleton (For 
recent review [21]). Based on these observations, one 
might expect that MEF2 may also control all or part of the 
fusion process during myogenesis.
MEF2 also Controls Myocyte Fusion
Few studies so far have provided direct evidence that 
MEF2 is a regulator of muscle cell fusion. In Drosophila, 
Arredondo et al. showed that CF2 (Drosophila Chorion 
factor 2), a MEF2 co-factor, is involved in the control of 
muscle size and of the number of nuclei in myofibers [22]. 
MEF2a-deficient murine C2C12 myoblasts have impaired 
ability to differentiate into myocytes but also exhibit lower 
levels of Myoferlin, which is critical for myogenic fusion, 
and of Palladin (Palld) and Formin-binding protein 
(Fnbp1l), which are involved in cytoskeleton dynamics 
and myocyte fusion [5]. Expression of singles bar gene 
in Drosophila, a protein linked to myocyte fusion, is also 
controlled by MEF2 [23].
The original goal of our study was to investigate the role 
of protein phosphatases during myogenesis [4]. Because 
protein kinases have long been known to be crucial in this 
process, the involvement of their counterpart, protein 
phosphatases would also be expected. Surprisingly, very 
few reports had addressed this issue when we started 
our project. Only three protein phosphatases had been 
shown to play a role in skeletal myogenesis and all three 
(i.e., calcineurin, protein phosphatase-1 and protein-
tyrosine phosphatase-α) were associated to myoblastic 
differentiation [24-26]. We decided to focus on PP2A 
because of the importance of class IIa HDACs during 
myogenesis and because of the PP2A ability to regulate 
these enzymes in other biological processes such as 
angiogenesis [27,28]. Our work showed that in myoblasts, 
PP2A controls HDAC4 phosphorylation levels and its 
repressive activity towards MEF2-directed transcription. 
PP2A is a trimeric holoenzyme made of a scaffolding A, 
catalytic C and B-type regulatory subunits. There are 
15 different B-type subunits, that are classified into four 
distinct families (PR55/B or B55, PR61B’ or B56, PR72B” 
and STRN/PR93/PR110/B”’) [29,30].
The nature of the B subunit found in the holoenzyme 
determines various characteristics of the complex, 
including substrate specificity. Consequently, among the 
approximately 80 unique heterotrimeric holoenzymes, 
each possesses its own substrate specificity related to a 
particular biological activity. In muscle cells, we succeeded 
in identifying HDAC4 as the specific substrate of PP2A 
holoenzymes containing the Bδ regulatory subunit. 
Interestingly, other class IIa HDACs were not regulated by 
PP2A-Bδ [4].
To our surprise, knocking down the Bδ subunit had no 
significant effects on myoblast differentiation. Instead it 
severely impacted the ability of differentiated myocytes to 
fuse together and form multinucleated myofibers [4]. Using 
a transcriptomic approach, we confirmed that knockdown 
of PP2A-Bδ led to the up-regulation of MEF2-dependent 
genes. However, only a subset of MEF2- dependent genes, 
mainly those related to the cytoskeleton (i.e., Sorbs2) were 
affected by knocking down PP2A-Bδ, while those involved 
in myoblast differentiation (i.e. Myogenin) remained 
unaffected.
Some of our observations might provide a possible 
explanation as to why the absence of PP2A-Bδ has no impact 
on myocyte differentiation. Indeed, we found that I1PP2A 
and I2PP2A, two protein PP2A inhibitors [31], were highly 
expressed in non- and early differentiating myoblasts. It 
is likely that the presence of these proteins would prevent 
any PP2A activity during the early stages of myogenesis 
(Figure 1). The absence of phosphatase activity directed 
towards class IIa HDACs would create a favorable context 
for phosphorylation of HDAC4 by myogenic kinases, 
which would in turn activate the MEF2-directed myoblast 
differentiation program. At the onset of myogenic fusion, 
levels of I1PP2A and I2PP2A are drastically reduced, thus 
allowing a fine control of HDAC4 phosphorylation levels 
by PP2A-Bδ-mediated dephosphorylation.
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A few months after our study was published, an article 
reported that HDAC4 expression levels were inversely 
correlated with the ability of myocytes to fuse and form 
myotubes [32]. In 2010, Sun et al. found that a mTOR–miR-
1–HDAC4–follistatin pathway was important for myocyte 
fusion [33]. In addition, mTOR and HDAC4 have both 
been connected to the endolysosomal pathway, which itself 
might be linked to myocyte fusion [34,35]. Knockdown of 
lysosomal associated protein 2 (LAMP-2), a key regulator 
of endolysomal biology, impairs myotube formation in 
C2C12 cells and LAMP-2 deficiency is associated with 
myopathies [35,36]. HDAC4 may regulate endolysosomal 
pH, a key feature in endolysosomal function, through the 
CREB-NEH6 axis [35]. Together with our observations, 
these studies point towards a key role for HDAC4 in the 
process of myogenic fusion. Autophagy, a lysosome-
mediated degradation pathway is activated during muscle 
cell differentiation and is required for in vitro myogenesis 
[36,37]. With regards to fusion, studies have shown that 
impaired autophagy is associated with reduced myotube 
formation [37], while others have reported opposite 
observations . Intriguingly, PP2A, HDAC4 and MEF2 have 
all been independently linked to the autophagic response 
[17,35,38,39]. It is thus tempting to speculate that in 
addition to cytoskeleton regulation, the PP2A-HDAC4-
MEF2 axis may also regulate myocyte fusion through 
activation of alternative pathways, including autophagy. 
However, we did not observe upregulation of autophagy-
related genes in PP2A-Bδ-deficient myocytes.
Collectively, our data refine the historical role of the 
HDAC4-MEF2 pathway in skeletal myogenesis and shed 
light on its ability to control both the differentiation 
and the fusion processes. Nevertheless, our work also 
leaves a number of unanswered questions: Are there any 
phosphatase(s) controlling the phosphorylation of other 
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Figure 1: Regulation of myocyte fusion by the PP2A Bδ/HDAC4/MEF2 pathway. MEF2-dependent transcription is 
under the control of HDAC4, which is controlled by reversible phosphorylation, which is controlled by the opposing 
actions of signal-responsive myogenic kinases and PP2A-Bδ. In proliferating myoblasts, the activity of myogenic 
kinases is minimal and therefore, the  phosphorylation  levels  of  HDAC4  are  low.  HDAC4  is  thus  bound  to 
MEF2  and  represses its transcriptional activity. At the onset of myogenesis, high HDAC4 phosphorylation is rapidly 
achieved by (i) activation of HDAC4 kinases by extracellular myogenic signals and (ii) low activity of PP2A Bδ due to 
the presence of I1/I2PP2A. Hyperphosphorylation of HDAC4 promotes its dissociation from MEF2 and activation of 
MEF2-regulated genes, including effectors of the differentiation programs and cytoskeleton regulators (e.g ArgBP2). 
As myocytes progress through differentiation, myogenic kinases are inactivated and I1/I2-PP2A levels drop, allowing 
activation of PP2A-Bδ. Consequently, phosphorylation of HDAC4 decreases, which allows reinstatement of its 
repression over MEF2. Shutdown of MEF2-dependent transcription by PP2A-Bδ terminates the genetic differentiation 
programs and prevents excessive accumulation of the fusion regulators allowing myoblast fusion to occur.
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class IIa HDACs that are also expressed in muscle cells 
(i.e. HDAC5, HDAC7 and HDAC9) [40]. Which processes, 
during myogenesis, are controlled by these unidentified 
phosphatases: differentiation, fusion, or both? What are 
the sets of MEF2-dependent genes that are specifically 
regulated by HDAC5, HDAC7 or HDAC9? Along this line, 
an exciting possibility would be that each class IIa HDAC 
phosphatase might ensure the control of specific subsets 
of MEF2-dependent genes. Beyond myogenesis, the 
question as to whether class IIa HDACs or MEF2 might 
also contribute to cell fusion in other biological processes 
requires further examination.
Interestingly, besides myogenesis, the control of 
cytoskeleton dynamics by the PP2A-MEF2 axis has 
also been linked to Alzheimer’s disease (AD). Tau, a 
microtubule-binding protein is hyperphosphorylated in 
amyloid plaques. This is a hallmark of AD and interestingly, 
PP2A-Bα is the major phosphatase regulating Tau 
phosphorylation [41]. Misregulation of PP2A activity leads 
to Tau hyperphosphorylation and aberrant microtubule 
dynamics. Therefore, pharmacological modulation of 
PP2A activity in AD has attracted a lot of attention [42]. To 
our knowledge, the role of PP2A-Bδ remains unexplored 
in neurodegenerative diseases, including AD. In contrast, 
mutations in MEF2c have also been associated to late-
onset of AD while recent observations pointed to a role 
for HDAC4 in amyloid beta clearance in ApoE4 astrocytes 
[43-45]. Based on our observations in myocytes, we believe 
that the potential involvement of the PP2A-Bδ-HDAC4-
MEF2 pathway in AD is an interesting line of investigation.
Therapeutic Perspectives
Protein phosphorylation is a key regulatory mechanism 
that is involved in virtually every signaling pathway in 
mammalian cells. Therefore, it is not surprising that 
dysregulation of protein phosphorylation has been linked 
to a plethora of diseases, such as cancer, inflammatory 
syndromes and Alzheimer’s disease to name only a few 
[46]. As of 2018, 38 kinase inhibitors had been approved 
for therapeutic use [47]. Although phosphatases are the 
opposing arm of protein phosphorylation regulation, they 
caught less attention than kinases as drug targets and the 
identification of phosphatase physiological substrates often 
remains a challenge [48]. For a long time, phosphatases 
were considered as non-optimal for pharmacological 
targeting because they were wrongly regarded as enzymes 
lacking specificity. Even if the growing knowledge about 
phosphatases and their substrates is slowing shifting this 
outdated paradigm, the development of phosphatase-
targeting drugs to modulate phosphorylation levels of 
disease proteins remains mostly uncharted territory.
Targeting PP2A is even more challenging because of the 
involvement of PP2A in a wide range of key biological 
processes. Potential drugs thus need to target only specific 
PP2A holoenzymes, in order to avoid major adverse effects, 
as illustrated by the lethal knock-down of PP2A catalytic 
subunits in mice [49]. Recently, Leonard et. al identified 
DT-061, a compound that specifically stabilizes the B56/
B’α-PP2A holoenzyme in an active state [50]. This finding 
paves the way towards the development of innovative 
therapeutics targeting PP2A holoenzymes [51]. In light 
of our findings, a drug that would lead to the specific 
activation of PP2A-Bδ holoenzyme may be useful to favor 
muscle regeneration in the multiple diseases associated 
with muscle loss, i.e. sarcopenia or myopathies.
Conclusions and Future Directions
Although MEF2 is undisputedly important for myogenesis 
in vitro, its role in in vivo models is far less characterized 
and requires further investigation [3]. Indeed, MEF2 seems 
to be more prominent for myogenesis in Drosophila than 
in vertebrates. In mouse and Zebrafish, MEF2 is important 
for muscle regeneration and sarcomere assembly but seems 
dispensable for myotome formation. The discrepancies 
between in vivo and in vitro observations may lie in the 
functional redundancies between MEF2 members or 
splicing isoforms.
Interestingly, the phenotype that we observed after 
PP2A-Bδ knockdown was similar both in vitro (C2C12 
mouse myoblasts model) and in vivo (zebrafish model). 
This suggests that interfering with regulators or partners 
might be a more profitable strategy when attempting to 
specifically modulate MEF2 biological functions.
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